Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/81—Protease inhibitors
  • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
  • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
  • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

• the invention relates to serine proteinase inhibitors, cDNA coding for serine proteinase inhibitors, medicaments containing the inhibitors or their coding nucleic acid, uses of the compounds according to the invention for the production of medicaments for the treatment of various indications, antibodies or antibody fragments against epitopes of the compounds according to the invention , Poly- or oligonucleotides that hybridize with genes of the compounds according to the invention, a diagnostic agent for detecting the compounds according to the invention, and medicaments containing antibodies or poly- or oligonucleotides according to the invention.
• proteolytic processes play an important physiological role in all organisms, whereby a distinction must be made between non-specific and specific proteolytic reactions.
• the first include, for example, digesting food in the digestive tract by endopeptidases and the intracellular degradation of used endogenous substances and phagocytosed material by lysosomal proteinases.
• Specific proteolyses are mostly used to convert a proenzyme into the active form as in the Conversion of trypsinogen to trypsin and chymotrypsinogen to chymotrypsin as well as in the kallikrein-kinin cascades and the blood coagulation cascade.
• serine proteinases e.g. chymotrypsin, trypsin, elastase and kathepsin G
• aspartate proteinases e.g. kathepsin D, cathepsin E and pepsin
• cysteine proteinases eg Kathepsin B, Kathepsin H and Kathepsin
• metallo-proteinases eg collagenase and thermolysin
• the organism has a number of other proteins, the proteinase inhibitors (for an overview, see Laskowski and Kato, 1980 and Bode and Huber, 1992).
• the human plasma proteinase inhibitors synthesized in the liver o ⁇ _-antichymotrypsin and ⁇ ⁇ -proteinase inhibitors protect the lung tissue against non-specific attack by the proteinases cathepsin G or elastase from polymorphonuclear lymphocytes.
• An imbalance between proteinases and their specific inhibitors can lead to pathological effects.
• an excessive ratio of elastase to ⁇ proteinase inhibitor in patients with a genetic deficiency in this factor increases the risk of developing pulmonary emphysema by about 20 to 30 times the normal population (Carrel and Owen, 1980).
• emphysema formation is promoted by oxidation of the amino acid methionine located in the reactive center of the ⁇ ⁇ proteinase inhibitor by oxidants contained in cigarette smoke (Miller and Kuschner, 1969; Ohlsson et al., 1980).
• the technical problem on which the invention is based is to provide further inhibitors of serine proteinases. Furthermore, the genes or cDNA coding for the inhibitors according to the invention should be made available.
• a specific feature of the serine proteinase inhibitors according to the invention is that the serine proteinase inhibitor has a domain with four cysteines and there is a sequence of 0 to 20 amino acids between the first and a second cysteine, or the serine proteinase inhibitor has a domain with six cysteines and there is a sequence of 7 to 20 amino acids between the first and second cysteines.
• sequence be selected from first and second cysteine
• HEFQAFMKNGKLF SEYRKSRKNGRLF
• a third and fourth cysteine is selected from
• serine proteinase inhibitor according to the invention is one of the formulas
• R 1 -C-HEFQAFMK ⁇ GKLF-C-PQDKKFFQSLDGIMFI ⁇ K-C-AT-CR 2 R.
• R ⁇ H 2 is an amino acid or a peptide with up to 100 amino acids and R 2 is COOH, CONH 2 , an amino acid or a peptide with up to 100 amino acids.
• the serine proteinase has one or more disulfide bridges. It is particularly preferred that it has a disulfide bridge between the first and fourth cysteine and / or the second and third cysteine or that it has between the first and fifth cysteine and / or the second and fourth cysteine and / or the third and sixth cysteine has a disulfide bridge.
• Preferred representatives of the serine proteinase inhibitors according to the invention are the compounds HF 6479 and HF 7665 and fragments of the proteins VAKTI-1 and VAKTI-2 according to FIGS. 1 and 2.
• FIGS. 1 to 3 also provide further information relating to the cDNA which codes for the compounds according to the invention. In particular, the corresponding motifs and primer hybridizing sites are given.
• the compound HF 3479 according to the invention has a mass of 6,479 daltons, that of HF 7665 is 7,665 daltons, both were purified from hemofiltrate.
• a cDNA coding for the compounds according to the invention in particular a cDNA with the nucleic acid sequence according to FIGS. 1 to 2, is also claimed according to the invention.
• the compounds according to the invention are suitable as medicaments. If necessary, they are applied together with pharmaceutically acceptable carriers.
• the medicaments according to the invention containing the proteinase inhibitors according to the invention are preferably administered in amounts of 1 to 100 mg / kg body weight of the patient. All pharmaceutical preparations for active peptides can be used as the administration form.
• the drugs containing nucleic acids according to the invention are preferably administered in amounts of 0.1 to 100 mg / kg body weight of a corresponding patient.
• galenical forms of administration are those which are suitable for the application of nucleic acids without the nucleic acids are made ineffective before reaching the site of action by metabolic influences.
• liposomes in which the nucleic acids are located can be used as the galenical administration form.
• the compounds according to the invention come in particular for the treatment of acute or chronic cervical inflammation, inflammation of the Bartholin's glands or other vaginal areas, tonsillitis, pharyngitis and laryngitis, acute or chronic inflammatory processes associated with excessive mucus formation and the resulting acute emergency situations, postoperative bleeding due to hyper - fibrinolysis and for the prophylaxis of pulmonary emphysema in c - ⁇ - proteinase inhibitor deficiency.
• the compounds according to the invention can be administered to compensate for endogenous deficits.
• the nucleic acids can also be used in gene therapy, directly or coupled to suitable vehicles. Attenuated adenoviruses, into which the corresponding genes are incorporated, are particularly suitable as suitable vectors.
• the polypeptides according to the invention can serve for the production of antibodies or antibody fragments. These are easily produced by immunizing suitable mammals.
• the antibodies can also be humanized by operations known per se, so that these antibodies can also be used therapeutically.
• Antibodies or antibody fragments can then be used to regulate diseases in which the proteinase inhibitors are pathologically expressed.
• antisense nucleic acids complementary to the nucleic acids according to the invention can be used for therapeutic use in the event of overexpression of the proteinase inhibitor genes.
• the compounds according to the invention can be prepared in a simple manner by methods of peptide or nucleotide synthesis which are known per se. None stands in the way of genetically engineering the compounds.
• fragments can also be used with the polypeptides according to the invention, provided that they retain the inhibitory properties of the serine proteinase inhibitors.
• the finding of such fragments is known to the person skilled in the art. This is done, for example, by targeted enzymatic cleavage of the compounds according to the invention.
• Modified amino acids can also be used in the side chains.
• N- and C-terminally modified polypeptides are also suitable.
• phosphorylated, glycosylated, methylated, acetylated or similarly modified polypeptides can be used, provided that they do not significantly impair the action of the serine proteinase inhibitors.
• nucleic acids according to the invention derivatives are also suitable which, depending on the codon usage, have modified triplet structures.
• nucleic acids according to the invention are also to be understood as those which are less degraded by nucleases than the native compounds, for example the corresponding SODN derivatives which are usually used in antisense technology, in order to make the antisense structures more stable against enzymatic attacks to design.
• polypeptide structures homologous with the polypeptides are also possible. These are in particular polypeptide structures in which amino acids are exchanged. For example, conservative amino acid substitutions in highly conserved regions can be taken into account as follows: each isoleucine, valine and leucine amino acid can be exchanged for another of these amino acids, aspartate can be exchanged for glutanate and vice versa, glutamine for asparagine and vice versa, serine versus trionine and vice versa.
• Conservative amino acid substitutions in less highly conserved regions can be as follows: each of the amino acids isoleucine, valine and leucine against every other amino acid, aspartate against glutamate and vice versa, glutamine against asparagine and vice versa, serine against theonine and vice versa, glycine against alanine and vice versa, alanine against Valine and vice versa, methionine against each of the amino acids leucine, isoleucine or valine, lysine against arginine and vice versa, one of the amino acids aspartate or glutamate against one of the amino acids arginine or lysine, histidine against one of the amino acids arginine or lysine, glutamine against glutamate and vice versa and Asparagine versus aspartate and vice versa.
• L-BABNA (6 mg / ml N ⁇ -benzoyl-L-arginine-p-nitroanilide hydrochloride)
• proteinase inhibitor (10 ⁇ M or 75 ⁇ g / ml HF 7665 in H 2 0).
• HF 7665 has an inhibitory effect on trypsin in a final concentration of approx. 1 ⁇ M or 7.5 ⁇ g / ml.
• no inhibitory effect of HF 7665 on chymotrypsin could be observed in a similar test.
• FIG. 3 shows that after the addition of HF 7665, the substrate conversion is reduced by approximately 30% due to trypsin inhibition.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Gastroenterology & Hepatology (AREA)
• Pulmonology (AREA)
• Pain & Pain Management (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Surgery (AREA)
• Rheumatology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Gynecology & Obstetrics (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Enzymes And Modification Thereof (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (5)

Publications (2)

Family

ID=26042785

Family Applications (1)

Country Status (8)

Families Citing this family (7)

Family Cites Families (4)

• 1998
  • 1998-12-23 US US09/582,328 patent/US7045594B1/en not_active Expired - Fee Related
  • 1998-12-23 WO PCT/EP1998/008424 patent/WO1999033974A1/fr active IP Right Grant
  • 1998-12-23 JP JP2000526631A patent/JP4358989B2/ja not_active Expired - Fee Related
  • 1998-12-23 EP EP98966667A patent/EP1040190B1/fr not_active Expired - Lifetime
  • 1998-12-23 AT AT98966667T patent/ATE292682T1/de not_active IP Right Cessation
  • 1998-12-23 CA CA2315976A patent/CA2315976C/fr not_active Expired - Fee Related
  • 1998-12-23 DE DE59812724T patent/DE59812724D1/de not_active Expired - Lifetime
  • 1998-12-23 ES ES98966667T patent/ES2241197T3/es not_active Expired - Lifetime
• 2009
  • 2009-07-08 JP JP2009161690A patent/JP2009273468A/ja active Pending

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events